WUXI BIOLOGICS (CAYMAN) INC.
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2269)

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND
(2) CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND NOMINATION COMMITTEE

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “Board”) of directors (the “Director(s)”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “Company”) is pleased to announce that Mr. Jackson Peter Tai (“Mr. Tai”) has been appointed as an independent non-executive Director with effect from May 6, 2023.

The biographical details of Mr. Tai are as follows:

Mr. Jackson Peter Tai, aged 72, has over 48 years of extensive experience in the banking, pharmaceutical and other industries. He held various key positions in DBS Group Holdings Limited (“DBS Group”) and DBS Bank Limited (“DBS Bank”), including Vice Chairman and Chief Executive Officer of DBS Group and DBS Bank from 2002 to 2007, President and Chief Operating Officer of DBS Group and DBS Bank from 2001 to 2002, Chief Financial Officer of DBS Bank from 1999 to 2001. He was also a director of DBS Bank (China) Limited from 2007 to 2008. From November 2013 to May 2023, Mr. Tai served as an independent non-executive director of Eli Lilly and Company, a company whose shares are listed on the New York Stock Exchange (stock symbol: LLY). From September 2016 to May 2023, Mr. Tai served as an independent non-executive director of HSBC Holdings plc (“HSBC”), a company whose shares are listed on the London Stock Exchange (stock symbol: HSBA) and the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (stock symbol: 0005), as well as the chairman of HSBC’s Group Risk Committee. He worked for 25 years in the investment banking division of J.P. Morgan & Co. Incorporated from 1974 to 1999, holding roles such as Chairman of Asia-Pacific Management Committee and Head of Japan Capital Markets.
Mr. Tai currently serves as a non-executive director of Mastercard Incorporated, a company whose shares are listed on the New York Stock Exchange (stock symbol: MA) since September 2008. Mr. Tai’s other previous non-executive roles include Singapore Airlines Limited, Bank of China Limited, Russell Reynolds Associates, Koninklijke Philips N.V., Canada Pension Plan Investment Board, ING Groep N.V., CapitaLand Limited, Singapore Telecommunications Limited and Jones Lang LaSalle Inc. Currently, Mr. Tai is a member of Harvard Business School Asia-Pacific Advisory Board and of the boards of The Metropolitan Opera, New York Philharmonic and Rensselaer Polytechnic Institute.

Mr. Tai obtained a bachelor of science degree from Rensselaer Polytechnic Institute in 1972 and a master’s degree in business administration (MBA) from Harvard Business School in 1974.

Save as disclosed above, Mr. Tai does not, at present, nor did he in the past three years, hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas.

Mr. Tai has entered into a director’s service agreement with the Company for a term of three years which is terminable by either party with three months’ written notice, and he is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Tai does not have any relationships with any Directors or senior management or substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Mr. Tai did not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Tai is entitled to a director’s remuneration of HK$1,200,000 per annum as determined by the Board with reference to Mr. Tai’s relevant experience and qualifications, his duties and responsibilities, the prevailing market conditions and the recommendation from the remuneration committee of the Board. The remuneration may be paid in the form of cash or restricted shares, or a combination of both (less any necessary statutory deductions), as agreed by the parties from time to time.

Save as disclosed above, there is no other information which is discloseable nor is/was Mr. Tai involved in any of the matters required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and there are no other matters relating to Mr. Tai’s appointment that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to extend its warmest welcome to Mr. Tai on his new appointment.
CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND NOMINATION COMMITTEE

The Board further announces that Mr. Tai has been appointed as the chairman of the audit committee of the Board (the “Audit Committee”) and a member of the nomination committee of the Board (the “Nomination Committee”), both with effect from May 6, 2023.

COMPLIANCE WITH THE LISTING RULES

Reference is made to the announcements of the Company dated November 25, 2022 and February 28, 2023 in relation to the passing away of Mr. Teh-Ming Walter Kwauk, a former independent non-executive Director, the former chairman of the Audit Committee and a former member of the Nomination Committee.

Following the above appointments of Mr. Tai with effect from May 6, 2023, the Company has fully complied with the requirements under Rules 3.10, 3.10A, 3.21 and 3.27A of the Listing Rules.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, May 8, 2023

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III and Mr. Jackson Peter Tai as independent non-executive Directors.

* For identification purpose only